Table 2.

Model of Obesity and Survival (Event-Free and Overall) by subtype, adjusted for hormonal therapy in Hormone Receptor Positive (HR+)/HER2− disease

Model of Obesity and Survival: Stratified by Subtype and Hormonal Therapy
		Obesity and EFS
		N	Events	HR (95% CI)	p-value
HR+/HER2−
AI	Obese (BMI 30+)	38	6	0.92 (0.32, 2.60)	0.87
	Not Obese (BMI<30)	51	9	1
Tamoxifen	Obese (BMI 30+)	8	4	2.47 (0.72, 8.49)	0.15
	Not Obese (BMI<30)	25	7	1
HER2+	Obese (BMI 30+)	37	7	3.37 (0.97–11.72)	0.06
	Not Obese (BMI<30)	57	4	1
TNBC	Obese (BMI 30+)	16	10	2.62 (1.03–6.66)	0.04
	Not Obese (BMI<30)	28	8	1

		Obesity and OS
		N	Deaths	HR (95% CI)	p-value
HR+/HER2−*
AI	Obese (BMI 30+)	38	2	0.45 (0.09–2.26)	0.34
	Not Obese (BMI<30)	51	6	1
Tamoxifen	Obese (BMI 30+)	8	3	9.27 (0.96–89.31)	0.05
	Not Obese (BMI<30)	25	1	1
HER2+	Obese (BMI 30+)	37	2	1.35(0.22–8.19)	0.75
	Not Obese (BMI<30)	57	3	1
TNBC	Obese (BMI 30+)	16	7	3.00 (0.95–9.51)	0.06
	Not Obese (BMI<30)	28	5	1

^*P-value for the interaction between obesity and hormonal therapy for HR+/HER2− is 0.23

^*P-value for the interaction between obesity and hormonal therapy for HR+/HER2− is 0.03

Abbreviations: AI – Aromatase Inhibitor, EFS – Event-Free survival, OS – Overall Survival, HR – Hazard Ratio, BMI – Body Mass Index, TNBC – Triple Negative Breast Cancer, HR – Hormone Receptor, CI – Confidence Interval